Clinical trials: Acquired Immune Deficiency Syndrome
HIV Infections
A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease
To determine the long-term safety and tolerance of four alternating and two intermittent regimens of zidovudine ( AZT ) and 2',3'-dideoxycytidine ( zalcitabine; ddC ) in the treatment of patients with advanced HIV disease who…
- Trial name
- NCT00000719
- Testing
- Zidovudine, Zalcitabine
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir…
- Trial name
- NCT01565850
- Testing
- D/C/F/TAF, DRV, COBI
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV HealthcareLLC.
- Trial name
- NCT01209065
- Testing
- GSK1349572, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at…
- Trial name
- NCT04250636
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Rockefeller University
Cardiovascular Diseases, Hepatitis C
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls.
- Conditions
- Cardiovascular Diseases, Hepatitis C, Hiv
- Trial name
- CHROME (NCT03823911)
- Testing
- Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
- Where
- 2 sites in United States
- Volunteers
- 87 people
- Sponsor
- University of Maryland, Baltimore
Hiv
HIV Care Cascade and Linkage to Antiretroviral Therapy Among Hospitalized Adults in Lusaka, Zambia
The population of inpatients is large in Zambia; however, because of poor linkages between hospitals and community HIV care, there are few data to analyze their engagement in HIV care before and after hospitalization.
- Trial name
- COLAH (NCT03158844)
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV/AIDS, Infant Morbidity
Impact of Point-of-Care EID for HIV-Exposed Infants
This mixed methods study will utilize a randomized step-wedge design to assess the impact of point-of-care (POC) versus conventional early infant diagnosis (EID) on key outcomes including timely return of results to caregivers…
- Conditions
- HIV/AIDS, Infant Morbidity, Pediatric HIV Infection, Transmission, Perinatal Infection
- Trial name
- POC-EID (NCT03824067)
- Testing
- Point of Care Early Infant Diagnosis, Standard of Care Early Infant Diagnosis
- Where
- 2 sites in Kenya, Zimbabwe
- Volunteers
- 9,539 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Depression
Antidepressant Treatment of AIDS Related Depression.
To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases.
- Trial name
- NCT00000390
- Testing
- Imipramine hydrochloride
- Where
- United States
- Sponsor
- GEIGY Pharmaceuticals
Substance Use Disorders, HIV/AIDS
Project Matter: Intervention to Improve HIV Self-care Among Men Who Have Sex With Men (MSM) With Substance Use Disorders
This study will implement a pilot randomized controlled trial (RCT, N=60) to assess the feasibility and acceptability a refined emotion regulation intervention designed to improve engagement in HIV-care among substance using HIV+…
- Conditions
- Substance Use Disorders, HIV/AIDS, Homosexuality, Male
- Trial name
- NCT03899220
- Testing
- Project Matter
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Human Immunodeficiency Virus
Effect of High Dose Vitamin D Supplementation on HIV Latency
HIV persists despite antiretroviral therapy (ART) and is associated with chronic inflammation. This inflammation is thought to prevent an effective immune response against the virus and is mediated at least in part by gut…
- Trial name
- VIVA (NCT03426592)
- Testing
- Vitamin D3, 10000 Intl Units Oral Capsule
- Where
- 4 sites in Australia
- Volunteers
- 30 people
- Sponsor
- University of Melbourne
Hypertriglyceridemia, HIV Infections
Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.
The purpose of this study was to assess the effect of soluble fiber® (partially hydrolyzed guar gum) supplementation on hypertriglyceridemia and immune profile in HIV-positive individuals on HAART.
- Trial name
- NCT00540111
- Testing
- soluble fiber® (partially hydrolyzed guar gum)
- Volunteers
- 19 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV Disease, Bipolar Disorder
Texting to Improve Adherence in HIV+ With Bipolar Disorder
Adherence to combination antiretroviral therapy (ART) is critical for successful HIV viral suppression. Nonadherence to ART poses several potentially serious health consequences, including higher viral loads, faster progression…
- Trial name
- iTAB (NCT02090634)
- Testing
- Psychoeducation, individualized Texting for Adherence Building (iTAB)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Diego
Infection, Human Immunodeficiency Virus
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF).
- Trial name
- NCT01384734
- Testing
- BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 254 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
To compare the antiviral activity, safety, toxicity, and steady-state pharmacokinetics of zidovudine, didanosine, and nevirapine used in combination in patients with HIV infection.
- Trial name
- NCT00000814
- Testing
- Nevirapine, Zidovudine, Didanosine
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 390 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
HIV Infections
Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda
According to the national guidelines in Uganda and to the World Health Organization guidelines, HIV-infected patients should receive cotrimoxazole prophylaxis indefinitely.
- Trial name
- CCS (NCT00674921)
- Testing
- cotrimoxazole
- Where
- Uganda
- Volunteers
- 1,650 people
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus
This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection.
- Conditions
- Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, HIV Infections
- Trial name
- NCT00499434
- Where
- Brazil
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Hiv
Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV
Prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood exposure to HIV.
- Trial name
- AES ODEFSEY (NCT03451032)
- Testing
- Non Interventional Study
- Where
- 6 sites in France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
HIV Infections, Insulin Resistance
Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine
The purpose of this study is to determine whether uridine supplementation will improve insulin sensitivity and overall carbohydrate metabolism in HIV-positive subjects who are currently undergoing treatment with antiretroviral…
- Conditions
- HIV Infections, Insulin Resistance, Hyperlactatemia
- Trial name
- NCT00471614
- Testing
- NucleomaxX (contains uridine)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
HIV-1 Infection
Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART.
- Trial name
- XTRA (NCT03212989)
- Testing
- Vorinostat, HXTC
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.